Teelbalkanker - Germcancer. informatie
Ervaringen van kankerpatienten met complementaire aanpak kunt u lezen onder uw verhaal - patientenervaringen. Ervaringen van kankerpatienten met complementaire aanpak op video kunt u bekijken als u hier klikt of op videoknop linksbovenaan deze pagina. Voorlichtingsvideo's over complementaire behandelingen kunt u bekijken op de website van het SNFK.
U kunt ons ondersteunen door een donatie te doen via het OPS inschrijvingsformulier.
Combinatie van Gemzar en Oxaliplatin lijkt levensverlengend voor teelbalkankerpatiënten waar eerdere chemo's bij faalden. Artikel update 28 april 2011
Ervaringen van kankerpatienten met complementaire aanpak kunt u lezen onder uw verhaal - patientenervaringen. Ervaringen van kankerpatienten met complementaire aanpak op video kunt u bekijken als u hier klikt of op videoknop linksbovenaan deze pagina. Voorlichtingsvideo's over complementaire behandelingen kunt u bekjken op de website van het SNFK.
25 september 2004: Bron Journal of Clinical Oncology 2004;22:108-114.
Combinatie van Gemzar en Oxaliplatin lijkt levensverlengend voor o.a. teelbalkankerpatiënten waar eerdere chemo's bij faalden.
Gemzar® Oxaliplatin Regimen Effective Salvage for Germ Cell Cancers Researchers from Germany have reported that the combination of Gemzar® and oxaliplatin can produce complete and partial responses in patients with refractory germ cell cancers. The results of this phase II clinical trial were reported in the January 1, 2004 issue of the Journal of Clinical Oncology.
Platinum-based chemotherapy is very effective and cures the majority of patients with advanced or metastatic germ cell cancers. Those who are not initially cured or are at high risk of relapse usually are treated with high-dose chemotherapy with autologous stem cell support. For patients who relapse after a stem cell transplant, therapeutic options are limited.
The recent German trial evaluated the combination of Gemzar® and oxaliplatin in 35 patients with refractory germ cell tumors. All patients had failed platinum-based therapy and 31 had also failed high-dose chemotherapy with autologous stem cell support. Half the patients had also received paclitaxel and 9 were classified as having “absolutely platinum-refractory disease”. Thus, this represented a heavily pre-treated group of patients who had all failed platinum-based therapies.
The authors reported that 3 patients had a CR and remain in remission from 4-16 months. Two other patients had disappearance of tumor markers and one of these remains in remission at two months. Eleven other patients had a partial response. The toxicity profile for this combination was reported to be tolerable toxicity. The authors concluded that “Gemzar® plus oxaliplatin demonstrates antitumor activity with acceptable toxicity in heavily pretreated patients with relapsed- or Platinol®-refractory GCT, and may offer a chance of long-term survival in selected patients.
Comments: Gemzar® and oxaliplatin appear to offer some hope for this very poor risk group of patients who have very few other treatment options.
Reference: Kollmannsberger C, Beyer J, Liersch R, et al. Combination Chemotherapy with Gemcitabine Plus Oxaliplatin in Patients with Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Group. Journal of Clinical Oncology 2004;22:108-114.
